| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: IOMI |
| Security Type |
Common Stock |
| Lead Underwriter |
UBS Investment Bank |
| Days In Registration |
121 |
| Date Filed |
3-Oct-2005 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Manufacturing |
| Business Description |
Iomai Corp, headquartered in Gaithersburg, Maryland, manufactures and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization. The company was founded in 1997. |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
16.9M |
| Contact |
- |
| Number of Employees |
66 |
|
| Original Filing Information |
| US |
| Shares Filed |
6.25M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
6.25M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
750.0K |
| File Amount |
$75.0M |
| File Price Range |
$13.00 - $11.00 |
| File Mid Price |
$12.00 |
Current Filing Information
(Amended 30-Jan-2006) |
|
US |
|
Shares Filed |
5.0M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
5.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$40.0M |
| · % Change from Original |
-46.67 |
| File Price Range |
$9.00 - $7.00 |
| File Mid Price |
$8.00 |
|
